Search clinical trials for: SAR3419

Total 10 results

Sanofi

Completed

Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma

Lymphoma | Non-Hodgkin

United States
Sanofi

Completed

SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma

Lymphoma | Non-Hodgkin

France
Sanofi

Terminated

SAR3419 in Acute Lymphoblastic Leukemia (MYRALL)

Acute Lymphocytic Leukaemia

United States, France
Sanofi

Completed

SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients (STARLYTE)

Diffuse Large B-cell Lymphoma

Belgium, Israel, Spain, Czechia, Turkey, Italy, United States, Poland, United Kingdom
SIMR (Australia) Biotech Pty Ltd.

Completed

A Study to Assess the Pharmacokinetics and Food Effect of SR419 in Healthy Subjects

Healthy

Australia
SIMR (Australia) Biotech Pty Ltd.

Completed

A Phase 1b Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419

Peripheral Neuropathic Pain

Australia
Shanghai SIMR Biotechnology Co., Ltd.

Completed

To Evaluate the Efficacy and Safety of SR419 in Patients With Postherpetic Neuralgia (PHN)

Postherpetic Neuralgia

China, Australia
Sanofi

Completed

Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

Norway, Austria, France
SIMR (Australia) Biotech Pty Ltd.
Syneos Health

Completed

The Safety, Tolerability, Pharmacokinetics(PK) of SR419 in Healthy Volunteers

Healthy Volunteers

Australia
Shanghai SIMRD Biotechnology Co., Ltd.

Completed

The Pharmacokinetics (PK), Safety, Tolerability of SR419 in Healthy Volunteers

Healthy

China

3

Subscribe